Compare ADMA Biologics Inc (ADMA) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Vanguard Ultra Short Bond ETF trades at $49.63. Which is the better fit depends on your goals.
| ADMA | VUSB | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $50.03 |
52-Week Low | $7.60 | $49.60 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VUSB trades at $49.66, up 0.04% with a bearish technical signal from moving averages. The ETF offers a yield around 4.35% and recent dividends of $0.17-$0.18, positioning it as a cash alternative amid potential Fed rate changes. Financial ratios are unavailable, but sentiment highlights its role in short-term bond strategies.
Outlook hinges on interest rate trends, with opportunities in yield advantage over money markets. Risks include credit and duration exposure. Analyst coverage is limited for this ETF, requiring investor due diligence on underlying holdings and macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
